Mirum Director Sells $400K Amid 91% Stock Surge -- Here's What the Firm Expects for 2026

6 days ago 4

Jonathan Ponciano, The Motley Fool

Mon, January 12, 2026 astatine 10:20 AM CST 4 min read

A manager astatine Mirum Pharmaceuticals sold 5,000 shares of the institution for $400,000 connected Dec. 22.
The full transaction was direct, involving the workout of vested banal options, instantly sold arsenic shares.
No indirect entities oregon trusts were involved.
These 10 stocks could mint the adjacent question of millionaires ›

Saira Ramasastry, a manager astatine Mirum Pharmaceuticals (NASDAQ:MIRM), executed the workout of 5,000 banal options followed by an contiguous open-market merchantability of the resulting shares for a full transaction worth of $400,000 connected Dec. 22, according to a caller SEC Form 4 filing.

Metric

Value

Shares sold (direct)	5,000
Transaction value	$400,000
Post-transaction communal shares (direct)

Transaction worth based connected SEC Form 4 weighted mean acquisition terms ($80.00); post-transaction worth is $0 arsenic nary communal shares remained aft the transaction.

What benignant of transaction occurred and however was it structured?
The transaction progressive the workout of 5,000 vested banal options by Saira Ramasastry, instantly followed by the merchantability of each resulting shares successful the unfastened market, with nary information from indirect entities oregon trusts.
How worldly was this lawsuit comparative to Ramasastry's wide ownership?
The merchantability accounted for 100% of her nonstop communal banal holdings.
What is the residual equity vulnerability post-transaction?
After this transaction, Ramasastry holds nary nonstop oregon indirect shares of communal stock, arsenic reported by the Form 4 filing.

Metric

Value

Revenue (TTM)	$471.79 million
Net income (TTM)	($41.42 million)
1-year terms change	90.71%

* 1-year show calculated utilizing Dec. 22 arsenic the notation date.

Mirum develops and commercializes therapies for uncommon and orphan liver diseases, with LIVMARLI arsenic its pb product, and further candidates specified arsenic Volixibat successful its pipeline.
The institution targets patients with uncommon liver disorders, including progressive familial intrahepatic cholestasis, Alagille syndrome, and biliary atresia.

Mirum is simply a biopharmaceutical institution specializing successful the improvement of innovative therapies for debilitating uncommon liver diseases.

Ramasastry’s transaction was executed nether a Rule 10b5-1 program and progressive exercising 5,000 options earlier instantly selling the resulting shares. Notably, she inactive holds 10,000 options, preserving upside vulnerability adjacent aft eliminating nonstop communal banal holdings. With shares up astir 91% implicit the past twelvemonth and acold outpacing the broader market, an enactment workout and merchantability nether a pre-set program similar this 1 looks much similar compensation mechanics than a displacement successful conviction.

Meanwhile, Mirum Pharmaceuticals continues to execute operationally. Preliminary 2025 results released connected Monday amusement nett merchandise income of astir $520 million, beating the precocious extremity of guidance, and absorption present forecasts $630 cardinal to $650 cardinal successful planetary nett merchandise income for 2026. The institution besides ended 2025 with an estimated $392 cardinal successful currency and investments and achieved affirmative operating currency flow, giving it flexibility to money pipeline enlargement and the projected Bluejay Therapeutics acquisition, which is expected to adjacent this month. "2025 was an fantabulous twelvemonth for Mirum, reflecting the spot and scalability of our purpose-built uncommon illness operating model," CEO Chris Peetz said successful the Monday release.